Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193641 | 0.99 | GRM5 (0.47) | GRM5GRM3KMT2AHRH3HSP90AA1 | |
| SCHEMBL304942 | 0.98 | GRM5 (0.46) | GRM5GRM3KMT2AHRH3HSP90AA1 | |
| SCHEMBL304170 | 0.85 | SIGMAR1 (0.49) | KMT2AHRH3ALDH1A1MEN1 | |
| SCHEMBL10193639 | 0.83 | SIGMAR1 (0.50) | KMT2AHRH3ALDH1A1MEN1 | |
| SCHEMBL10193638 | 0.83 | HRH3 (0.51) | KMT2AHRH3HSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL15751213 | 0.83 | GRM5 (0.43) | GRM5GRM3KMT2AHRH3HSP90AA1 | |
| SCHEMBL304941 | 0.83 | GRM5 (0.43) | GRM5GRM3KMT2AHRH3HSP90AA1 | |
| SCHEMBL304172 | 0.82 | SIGMAR1 (0.49) | KMT2AHRH3ALDH1A1MEN1 | |
| SCHEMBL800085 | 0.78 | GRM5 (0.47) | GRM5GRM3KMT2AHRH3HSP90AA1 | |
| SCHEMBL304833 | 0.77 | ALDH1A1 (0.46) | KMT2AALDH1A1POLBMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9115079-B2 | NDM inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-20140221330-A1 | NDM INHIBITOR | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2737900-A1 | NDM INHIBITOR | Meiji Seika Pharma Co., Ltd. (JP) | 2014-06-04 | — | — | EP | disclosed |
| CN-101267815-B | metallo-beta-lactamase inhibitors | MEIJI SEIKA PHARMA CO LTD | 2013-11-06 | — | — | CN | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| CN-101267815-A | metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA (JP) | 2008-09-17 | — | — | CN | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | GRM5 1865/4885GRM3 3672/4885KMT2A 1979/4885 |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | GRM5 1865/4885GRM3 3672/4885KMT2A 1979/4885 |
| US-20140221330-A1 | NDM INHIBITOR | MGAM, NQO1, NQO2 | GRM5 1590/4885GRM3 3343/4885KMT2A 1883/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | GRM5 2031/4885GRM3 3776/4885KMT2A 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.